GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Golden Throat Holdings Group Co Ltd (HKSE:06896) » Definitions » EBIT

Golden Throat Holdings Group Co (HKSE:06896) EBIT : HK$419 Mil (TTM As of Jun. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Golden Throat Holdings Group Co EBIT?

Golden Throat Holdings Group Co's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2024 was HK$190 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was HK$419 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Golden Throat Holdings Group Co's annualized ROC % for the quarter that ended in Jun. 2024 was 26.53%. Golden Throat Holdings Group Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 71.86%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Golden Throat Holdings Group Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 16.61%.


Golden Throat Holdings Group Co EBIT Historical Data

The historical data trend for Golden Throat Holdings Group Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Golden Throat Holdings Group Co EBIT Chart

Golden Throat Holdings Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 255.63 238.73 299.78 431.37 406.58

Golden Throat Holdings Group Co Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 94.00 341.82 177.00 229.58 189.65

Competitive Comparison of Golden Throat Holdings Group Co's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Golden Throat Holdings Group Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Golden Throat Holdings Group Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Golden Throat Holdings Group Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Golden Throat Holdings Group Co's EV-to-EBIT falls into.


;
;

Golden Throat Holdings Group Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$419 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Golden Throat Holdings Group Co  (HKSE:06896) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Golden Throat Holdings Group Co's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=356.19 * ( 1 - 21.06% )/( (1059.125 + 1060.608)/ 2 )
=281.176386/1059.8665
=26.53 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2514.638 - 282.763 - ( 1172.75 - max(0, 773.181 - 1988.086+1172.75))
=1059.125

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2232.228 - 299.633 - ( 1119.873 - max(0, 840.235 - 1712.222+1119.873))
=1060.608

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Golden Throat Holdings Group Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Jun. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=379.308/( ( (489.822 + max(81.928, 0)) + (483.959 + max(-115.914, 0)) )/ 2 )
=379.308/( ( 571.75 + 483.959 )/ 2 )
=379.308/527.8545
=71.86 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(60.946 + 69.137 + 274.017) - (282.763 + 0 + 39.409)
=81.928

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(45.651 + 94.208 + 43.888) - (299.633 + 0 + 0.028000000000134)
=-115.914

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Golden Throat Holdings Group Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2024 )
=419.238/2524.123
=16.61 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Golden Throat Holdings Group Co EBIT Related Terms

Thank you for viewing the detailed overview of Golden Throat Holdings Group Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Golden Throat Holdings Group Co Business Description

Traded in Other Exchanges
N/A
Address
No. 28, Fengxiang Road, Guangxi Zhuang. Autonomous Region, Liuzhou, CHN
Golden Throat Holdings Group Co Ltd is an investment holding company. Through its subsidiaries, the company is engaged in the manufacture and sale of pharmaceuticals, healthcare food and other products. It manufactures and sells lozenges and other pharmaceutical and food products. The key products of the group that derives revenue for the group are Golden Throat Lozenges (OTC), Golden Throat Lozenge Series products and other products. The group derives revenue from Mainland China.

Golden Throat Holdings Group Co Headlines

No Headlines